** Shares of gene therapy developer Lexeo Therapeutics
rise 13.62% to $8.74 premarket
** Co says reached alignment with FDA on registrational development plan for LX2006 to support an accelerated approval pathway
** LX2006 is being developed as a gene therapy that is delivered intravenously for the treatment of Friedreich's ataxia cardiomyopathy
** Friedreich's ataxia is a genetic multi-system disorder and 80% of patients are estimated to develop cardiomyopathy, a type of heart disease
** LX2006 was granted regenerative medicine advanced therapy (RMAT) designation to accelerate development - LXEO
** Brokerage Stifel says alignment is a big win
** Up to last close, stock down ~42% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.